Methylcobalamin Injections Each 1 ml contains 1000 mcg of methylcobalamin
Current animal model systems do not fully recapitulate the pathophysiological conditions in human IC/BPS, and targeting specific molecular pathway disruption in animal models might serve as a better option than existing models
Peptides referenced below are research compounds and, in some cases, the active ingredients in FDA-approved finished pharmaceutical products
Thus, while we were not successful in obtaining more reactive analogs at this point, this approach allows us to explain the observed low reactivity at physiological pH and offers a valuable tool for guiding the future design of nucleotide-based inhibitors with optimized preorientation and reactivity profiles, providing a systematic framework for enhancing these compounds reactivities in a targeted manner
For example, a review by Gwyer and colleagues (2019) concluded that while studies have reported findings across experimental models, the majority of the evidence comes from laboratory and animal research
